Close
  Indian J Med Microbiol
 

Figure 4: Forest plot highlighting the impact of evogliptin after 24 weeks of therapy on (a) HbA1c (as compared to ACG); (b) fasting glucose (as compared to ACG); (c) percent of people achieving HbA1c <7% (as compared to ACG); (d) percent of people achieving HbA1c <6.5% (as compared to ACG); (e): HbA1c (as compared to PCG); and (f): Fasting glucose (as compared to PCG) RCT: randomized controlled trial. ACG: active control group; PCG: passive control group ACG: active control group; PCG: passive control group

Figure 4: Forest plot highlighting the impact of evogliptin after 24 weeks of therapy on (a) HbA1c (as compared to ACG); (b) fasting glucose (as compared to ACG); (c) percent of people achieving HbA1c <7% (as compared to ACG); (d) percent of people achieving HbA1c <6.5% (as compared to ACG); (e): HbA1c (as compared to PCG); and (f): Fasting glucose (as compared to PCG) RCT: randomized controlled trial. ACG: active control group; PCG: passive control group  ACG: active control group; PCG: passive control group